First preclinical studies support cystobactamids as rapidly bactericidal, resistance-breaking drugs, which could become a powerful tool in fighting hospital-acquired and ventilator-associated pneumonia and bloodstream infections caused by resistant strains of Acinetobacter baumannii.
The selection of Myxobiotics by INCATE highlights its potential and provides the team with access to top-level advice and expertise from a community of distinguished scientists, industry representatives and investors. In addition, it receives non-dilutive funding of up to 10,000 EUR over the next 6 months and up to 250,000 EUR on progressing to the second phase of INCATE’s support program. INCATE was initiated last year as a pan-European private–public partnership to accelerate innovations that help combat the rising threat of antimicrobial resistance.
Ascenion, the HZI’s technology transfer partner, has been working with the scientists for years, building a comprehensive IP position around their work, and actively supporting translation as well as start-up preparation.
